|
May 13
|
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
|
|
May 7
|
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
|
|
Apr 30
|
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
|
|
Apr 1
|
DURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call Transcript
|
|
Mar 27
|
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
|
|
Mar 27
|
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
|
Mar 20
|
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
|
|
Mar 4
|
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
|
|
Nov 14
|
Q3 2023 DURECT Corp Earnings Call
|
|
Nov 7
|
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
|
|
Aug 10
|
Q2 2023 DURECT Corp Earnings Call
|
|
Aug 9
|
Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 9
|
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update
|